← back to search

Hong Tian

China Pharmaceutical University · CN
Area of research
Ophthalmology · Molecular Biology
Research interest
Research interests include Retinal Diseases and Treatments, Retinal Development and Disorders, Glaucoma and retinal disorders, and Ubiquitin and proteasome pathways.
h-index
16
citations
1,065
works
52
NIH funding
primary concept
email

Recent publications

Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy
Cellular and Molecular Life Sciences 2022cited by 22position: middledoi
Profiling disease-selective drug targets: From proteomics to ligandomics
Drug Discovery Today 2022cited by 10position: middledoi
Neurovascular regulation in diabetic retinopathy and emerging therapies
Cellular and Molecular Life Sciences 2021cited by 64position: middledoi
Selectively targeting disease‐restricted secretogranin III to alleviate choroidal neovascularization
The FASEB Journal 2021cited by 14position: middledoi
Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety
Angiogenesis 2019cited by 29position: middledoi
Secretogranin III as a novel target for the therapy of choroidal neovascularization
Experimental Eye Research 2019cited by 21position: middledoi
Function-first ligandomics for ocular vascular research and drug target discovery
Experimental Eye Research 2019cited by 16position: middledoi
Ligandomics: a paradigm shift in biological drug discovery
Drug Discovery Today 2018cited by 17position: lastdoi
Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy
The Journal of Experimental Medicine 2017cited by 48position: middledoi
Secretogranin III: a diabetic retinopathy-selective angiogenic factor
Cellular and Molecular Life Sciences 2017cited by 30position: lastdoi
Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease
Angiogenesis 2017cited by 26position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wei Li · Texas Tech University10 papers (2017–2022)Keith A. Webster · University of Miami6 papers (2017–2022)Michelle E. LeBlanc · Massachusetts Eye and Ear Infirmary5 papers (2017–2019)Prabuddha Waduge · Baylor College of Medicine3 papers (2021–2022)Liyang Ji · University of Miami3 papers (2021–2022)Yanli Ji · Sichuan University3 papers (2017–2019)Weiwen Wang · BGI Group (China)3 papers (2017–2019)Ping Chen · Information Technology Institute2 papers (2017–2019)Xiuping Chen · First Affiliated Hospital of Jiangxi Medical College2 papers (2017–2017)Iok‐Hou Pang · University of North Texas2 papers (2018–2022)Dan Liang · Kunming Medical University1 papers (2019–2019)Lili Hao · Sun Yat-sen University1 papers (2021–2021)Yan Wu · Central South University1 papers (2021–2021)Wencui Wan · First Affiliated Hospital of Zhengzhou University1 papers (2021–2021)Liu Yang · Southwest Medical University1 papers (2019–2019)Xin Rong · Pfizer (United States)1 papers (2019–2019)Mário Thiego Fernandes Pacheco · University of Miami1 papers (2018–2018)Xuxiang Zhang · Harbin Medical University1 papers (2019–2019)Chen Shen · Qingdao University1 papers (2017–2017)Chang Dai · Guangdong Academy of Medical Sciences1 papers (2022–2022)